Controversy has surrounded the use of renin–angiotensin–aldosterone system (RAAS) inhibitors, including angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB), in the setting of COVID-19. Here, ACE is linked to COVID-19.